A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model

Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncol Lett
Huvudupphovsmän: Chuang, Hui-Yen, Tyan, Yeu-Sheng, Hwang, Jeng-Jong, Shih, Kuang-Chung, Lin, Wei-Chan
Materialtyp: Artigo
Språk:Inglês
Publicerad: D.A. Spandidos 2021
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7933744/
https://ncbi.nlm.nih.gov/pubmed/33692869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12598
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk